My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Neuropace, Inc. - Common Stock (NQ:NPCE)

16.59 +0.85 (+5.40%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Neuropace, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 20, 2025

Via ACCESS Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 18, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 15, 2025

From Pomerantz LLP

Via GlobeNewswire

Analyst Expectations For NeuroPace's Future ↗

May 28, 2025

Via Benzinga

What 4 Analyst Ratings Have To Say About NeuroPace ↗

March 05, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 10, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

June 06, 2025

From Pomerantz LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, Inc. - NPCE

June 02, 2025

From Pomerantz LLP

Via GlobeNewswire

Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May ↗

May 31, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

May 30, 2025

Via Benzinga

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

May 28, 2025

From Pomerantz LLP

Via GlobeNewswire

This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

May 28, 2025

Via Benzinga

Here are the top movers in Tuesday's session. ↗

May 27, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 27, 2025

Via Benzinga

Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data? ↗

May 27, 2025

NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA pathway discussions.

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

May 27, 2025

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

Dow Surges Over 600 Points; US Durable Goods Orders Fall in April ↗

May 27, 2025

Via Benzinga

Topics Stocks

There are notable gap-ups and gap-downs in today's session. ↗

May 27, 2025

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Nasdaq Jumps Over 300 Points On EU Tariff Delay; AutoZone Posts Downbeat Earnings ↗

May 27, 2025

Via Benzinga

Tower Semiconductor Posts Upbeat Earnings, Joins Nutex Health, Kornit Digital, Tencent Music Entertainment And Other Big Stocks Moving Higher On Wednesday ↗

May 14, 2025

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

Kura Sushi Posts Downbeat Results, Joins Cal-Maine Foods And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

April 09, 2025

Via Benzinga

NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual Meeting

April 08, 2025

From NeuroPace, Inc.

Via GlobeNewswire

NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting

April 03, 2025

Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentation

From NeuroPace, Inc.

Via GlobeNewswire

Earnings Scheduled For March 4, 2025 ↗

March 04, 2025

Via Benzinga

Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

January 07, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 26, 2024

Via Benzinga

MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

December 26, 2024

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.

Via Benzinga

Topics Stocks

Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket ↗

December 26, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.